###### Strengths and limitations of this study

-   This study is one of the largest investigating the incidence of adverse drug events (ADEs) in the Middle East.

-   This study is limited by a lack of hospitals from small towns and rural areas, and these settings may have an even higher incidence of ADEs.

-   Our study findings are not generalisable to overall Saudi Arabia because the study was conducted in Riyadh only.

Introduction {#s1}
============

[a]{.smallcaps}dverse drug events ([ade]{.smallcaps}s) are a major cause of morbidity, mortality and increased healthcare costs and hospitalisation.[@R1] [a]{.smallcaps}n ADE is defined as an injury caused by a medication.[@R4] [t]{.smallcaps}hey are largely preventable and occur mostly at the prescribing stage of the medication use process.[@R2] [@R4] [@R5] The incidence of ADEs reported in the literature varies significantly between countries, largely because of the differences in available drug products, practices, training, study methodology and patient safety initiatives among countries. Early in 1995, Bates *et al*[@R2] reported an incidence of 6.5 per 100 admissions in the USA; however, using the same methods, a study in Japan reported an incidence of 17 per 100 admissions,[@R4] suggesting real differences between these two countries. In Saudi Arabia, a single hospital study reported an incidence of 8.5 per 100 admissions,[@R5] and a cross-sectional study in Morocco reported an incidence of 4.2 per 100 admissions.[@R6] A recent international study using hospital datasets estimated the prevalence of ADEs to be 3.2% in England, 4.8% in Germany and 5.6% in the USA.[@R7] It is important to mention that the incidence of preventable ADEs was estimated by a population-based study to be 13.8 per 1000 person-years.[@R8]

Despite the evidence that [ade]{.smallcaps}s are common and could be life-threatening, little attempt has been made in Saudi Arabia to detect and estimate the incidence of ADEs in hospitalised patients. Such a paucity of research hinders the development of prevention strategies to improve patient safety[. T]{.smallcaps}o date, one prospective chart review study has been conducted in a single teaching hospital in the Saudi setting.[@R5] [t]{.smallcaps}herefore we sought to estimate incident ADEs in a larger patient sample from different hospitals with diverse settings and varying practices and strategies for managing patients[. T]{.smallcaps}herefore, the objective of our study was to estimate the incidence and risk factors associated with [ade]{.smallcaps}s in Saudi hospitals and determine their severity and preventability.

Methods {#s2}
=======

Study design and setting {#s2a}
------------------------

The [ade]{.smallcaps}s in Saudi Arabia (ADESA) project was a 4-month prospective cohort study involving four hospitals with diverse settings. These hospitals included a 900-bed tertiary teaching hospital, a 400-bed private hospital, a 1400-bed large government hospital and a 350-bed small government hospital. We randomly selected medical, surgical and intensive care units (ICUs) from these hospitals and excluded obstetrics and paediatric units because of the lower frequency of use of medications within these units. We included patients older than 12 years of age admitted for more than 24 hours during the 4-month study period. None of the hospitals had electronic medical records or decision support systems. Instead, hospitals used paper-based systems where physician notes (including prescribed medications) and nursing notes (including daily administered medications) were handwritten and kept in patient charts. Medication orders were sent to the inpatient pharmacies and dispensed using unit dose systems.

Definitions {#s2b}
-----------

Each incident was defined as an ADE (preventable and non-preventable), potential ADE (PADE) (which was classified as either intercepted or non-intercepted), or a medication error with low risk of causing harm. We defined ADE as any injury resulting from medical interventions related to a drug and includes both adverse drug reaction (ADR) in which no error occurred and complications resulting from medication errors.[@R2] [@R9] [@R10] Non-preventable ADEs, also known as ADRs, are defined by the WHO as 'a response to a drug which is noxious and unintended, and which occurs at doses used in man for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function'.[@R11] A non-preventable ADE is an injury with no error in the medication process. An example of this would be an allergic reaction in a patient not previously known to be allergic to that particular medication. Preventable ADEs were those that result from medication errors at any stage of the medication use process.[@R2] An example of this would be an anaphylactic reaction to an antibiotic that the patient is known to be allergic to. Preventability was further classified into definitely preventable/non-preventable and probably preventable/non-preventable. A PADE was an error that carries a risk of causing injury related to the use of a medication but harm did not occur, either because of specific circumstances or because the error was intercepted.[@R9] Intercepted PADEs were those that had the potential to cause injury but did not reach the patient because they were intercepted by someone during the medication use process. Non-intercepted PADEs were those with the potential to cause harm but failed to do so after the medication reached the patient.[@R9] Medication errors with a low risk of causing harm included those with minimal risk to cause ADEs or PADEs. Comorbidities were determined using Charlson\'s Comorbidity Index, which is a method of classifying comorbidities of patients according to the International Classification of Disease (ICD). Each comorbidity class has an associated weight of 1, 2, 3 or 6. The sum of all weights results in a single comorbidity score for each patient, with higher scores predictive of adverse outcomes such as mortality or high resource use.

Data collection and classification of incidents {#s2c}
-----------------------------------------------

Data were collected as described in detail elsewhere.[@R5] Briefly, trained clinical pharmacists collected data each day during the study period. In addition, all nurses working in the particular units were invited to attend monthly in-service presentations on the study to increase their awareness about ADE reporting. The pharmacists reviewed patients\' medical charts of all admitted patients in each of the participating units to report demographic characteristics of patients, comorbidity, and the number of medications. When incidents were noted, the pharmacists wrote a detailed description of each incident and captured the relevant patient characteristics and event history.

Two independent clinicians who were not involved in the data collection process were provided with a study manual that contained study terminology and a guide on the assessment of the severity and preventability of an incident. The manual included examples of incidents and their severity classifications. The severity of the incidents was categorised as significant, serious, life-threatening or fatal using a methodology developed by the Brigham and Women\'s Hospital\'s Center for Patient Safety Research and Practice.[@R2] The study manual served as a guide for the reviewers to independently review the incidents and decide on inclusion of incidents and further classify them as ADEs, PADEs or medication errors with low risk of causing harm. They were then able to assess severity and preventability. Preventability categories were defined as follows: definitely preventable, probably preventable, definitely not preventable or probably not preventable.[@R2] In the event of disagreement on the classification of the incidents, the clinicians called for a meeting to decide whether to include or exclude the incidents. The primary outcomes of this study were incidence of ADEs, PADEs and medication errors with low risk of causing harm, as defined previously. The secondary outcomes were the severity of events, their preventability, and associated risk factors. The research and ethics committees of the four hospitals approved this study.

Data analysis {#s2d}
-------------

We calculated the overall incidence per 100 admissions and crude rate per 1000 patient-days with 95% CIs. In addition, the incidence was calculated by hospital and by unit type. Continuous variables are presented as mean±SD and categorical variables as number and percentage. Inter-rater reliability was assessed using the κ statistic for assessment of the presence of an ADE and its preventability and severity. To evaluate the univariate association of potential risk factors with ADEs, we used univariate logistic regression. The variables included in the univariate analysis were age, gender, Charlson\'s Comorbidity Index weight, length of hospital stay, number of medications, and service type. Variables found to be statistically significant (p\<0.05) in the univariate analysis were included in the multivariate logistic regression final model. Statistical analyses were conducted using SPSS software V.22.0.

Results {#s3}
=======

Demographic characteristics of the patients {#s3a}
-------------------------------------------

Clinical pharmacists reviewed the medical charts of 4041 patients. Complete data for 3985 patients were analysed ([table 1](#BMJOPEN2015010831TB1){ref-type="table"}). The total length of hospital stay for patients was 30 996 days. The study was conducted in four hospitals in Riyadh, Saudi Arabia (977 patients from a teaching hospital, 2033 patients from a private hospital, 683 patients from a large government hospital, and 292 patients from a small government hospital). There was a slight majority of male patients (52.7%) ([table 1](#BMJOPEN2015010831TB1){ref-type="table"}). The patients were admitted to one of the three services (medical, 1352; surgery, 1771; ICU, 862). The mean length of hospital stay was 8.1±10.2 days and the mean age of the patients was 43.4±19.0 years ([table 1](#BMJOPEN2015010831TB1){ref-type="table"}).

###### 

Demographic characteristics of 3985 patients admitted to four hospitals in Riyadh

  Characteristic                             Frequency (%)   Mean±SD
  ------------------------------------------ --------------- -----------
  Gender                                                     
   Male                                      2102 (52.7)     --
   Female                                    1883 (47.3)     --
  Hospital type                                              
   Hospital 1 (teaching hospital)            977 (24.5)      --
   Hospital 2 (private hospital)             2033 (51.1)     --
   Hospital 3 (large government hospital)    683 (17.1)      --
   Hospital 4 (small government hospital)    292 (7.3)       --
  Service                                                    
   Medicine                                  1352 (33.9)     --
   Surgery                                   1771 (44.5)     --
   Intensive care unit                       862 (21.6)      --
  Age, years                                 --              43.4±19.0
  Length of hospital stay, days              --              8.1±10.2
  Comorbidities (Charlson\'s Index weight)   --              1.1±1.4
  Number of medications                      --              2.5±2.9

Incidents review and classification {#s3b}
-----------------------------------

The pharmacists\' chart reviews in the four hospitals identified 1676 cases of ADEs, PADEs and medication errors. Physicians reviewed and accepted 1531 (91.3%) of the cases, which were classified as 609 (39.8%) medication errors with low risk of harm, 677 (44.2%) PADEs, and 245 (16%) ADEs ([figure 1](#BMJOPEN2015010831F1){ref-type="fig"}). Among the ADEs, 85 (34.7%) were deemed preventable and 160 (65.3%) were judged to be non-preventable ([table 2](#BMJOPEN2015010831TB2){ref-type="table"}). The majority of the preventable ADEs occurred at the prescribing stage (75; 88.2%) followed by the administering stage (7; 8.2%), dispensing stage (2; 2.4%) and monitoring stage (1; 1.2%). Over half (129 (52.7%)) of the ADEs were significant, 91 (37.1%) were serious, 22 (9%) were life-threatening, and 3 (1.2%) were fatal. Of the 85 preventable ADEs, 36 (42.4%) were significant, 38 (44.7%) were serious, 10 (11.9%) were life-threatening and 1 (1.2%) was fatal. Among PADEs, 213 (31.9%) were intercepted by the medical staff. Regarding severity of PADEs, 383 (56.6%) were significant, 271 (40%) were serious and 23 (3.4%) were life-threatening.

###### 

Overall incidence of adverse drug events (ADEs), potential ADEs (PADEs) and medication errors with low risk of causing harm

                                                    Number of incidents (N=1531)   Per cent   Incidence per 100 admissions (95% CI)   Crude rate per 1000 patient-days (95% CI)
  ------------------------------------------------- ------------------------------ ---------- --------------------------------------- -------------------------------------------
  Medication errors with low risk of causing harm   609                            39.8       15.3 (14.1 to 16.5)                     19.6 (18.7 to 21.2)
  PADEs                                             677                            44.2       16.9 (15.7 to 18.3)                     21.8 (20.2 to 23.5)
  Intercepted PADEs (n=213)                                                                   5.3 (4.6 to 6.1)                        6.8 (5.9 to 7.8)
  Not intercepted PADEs (n=464)                                                               11.6 (10.6 to 12.7)                     14.9 (13.6 to 16.3)
  ADEs (harm)                                       245                            16         6.1 (5.4 to 6.9)                        7.9 (6.9 to 8.9)
  Preventable ADEs (n=85)                                                                     2.1 (1.7 to 2.6)                        2.7 (2.2 to 3.3)
  Non-preventable ADEs (n=160)                                                                4.0 (3.4 to 4.6)                        5.1 (4.4 to 6.0)

Medication errors with low risk of causing harm include those with low risk of causing ADEs or PADEs.

![Study flow chart.](bmjopen2015010831f01){#BMJOPEN2015010831F1}

Overall incidence of ADEs and medication errors with low risk of causing harm {#s3c}
-----------------------------------------------------------------------------

The incidence of ADEs per 100 admissions was 6.1 (95% CI 5.4 to 6.9) and the incidence of PADEs was 16.9 (95% CI 15.7 to 18.3) per 100 admissions ([table 2](#BMJOPEN2015010831TB2){ref-type="table"}). The incidence of medication errors with low risk of causing harm was 15.3 (95% CI 14.1 to 16.5) per 100 admissions, and the incidence of preventable ADEs was 2.1 (95% CI 1.7 to 2.6) per 100 admissions. The incidence of non-preventable ADEs was 4.0 (95% CI 3.4 to 4.6) per 100 admissions, and the incidence of intercepted PADEs was 5.3 (95% CI 4.6 to 6.1) per 100 admissions ([table 2](#BMJOPEN2015010831TB2){ref-type="table"}). Incidents of preventable ADEs, PADEs and medication errors with low risk of causing harm most commonly occurred at the prescribing stage (1288 (84.1%)), followed by the dispensing stage (69 (4.5%)) and the administering stage (43 (2.8%)). [Table 3](#BMJOPEN2015010831TB3){ref-type="table"} shows the distribution of incidents among the four hospitals. Examples of PADEs at different stages of the medication use process are listed in [online supplementary appendix](#SM1){ref-type="supplementary-material"} A. The incidence of ADEs was highest in the large government hospital (16.6 (95% CI 13.5 to 20.2) per 1000 patient-days and 32.9 (95% CI 27.7 to 38.4) per 100 admissions) followed by the teaching hospital (8.7 (95% CI 6.9 to 10.6) per 1000 patient-days and 8.5 (95% CI 6.8 to 10.4) per 100 admissions) ([table 3](#BMJOPEN2015010831TB3){ref-type="table"}).

###### 

Classification of adverse drug events (ADEs) by hospital type

  Units        ADEs   Length of hospital stay (days)   ADE crude rate per 1000 patient-days (95% CI)   Number of admissions   ADE incidence per 100 admissions (95% CI)
  ------------ ------ -------------------------------- ----------------------------------------------- ---------------------- -------------------------------------------
  Hospital 1   83     9585                             8.7 (6.9 to 10.6)                               977                    8.5 (6.8 to 10.4)
  Hospital 2   53     9032                             5.9 (4.4 to 7.6)                                2033                   2.6 (2.1 to 3.3)
  Hospital 3   13     6613                             2.1 (1.1 to 3.2)                                683                    2.1 (1.1 to 3.2)
  Hospital 4   96     5766                             16.6 (13.5 to 20.2)                             292                    32.9 (27.7 to 38.4)

Hospital 1, teaching hospital; Hospital 2, private hospital; Hospital 3, small government hospital; Hospital 4, large government hospital.
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The incidence of PADEs was predominantly higher in the private hospital (367; 23.9%). Medication errors were mostly seen in the private hospital (367; 23.9%).

Classification of ADE incidents by service type {#s3d}
-----------------------------------------------

The incidence of ADEs was highest in the ICUs at 13.7 (95% CI 11.6 to 16.1) per 1000 patients-days and 17.4 (95% CI 14.7 to 20.3) per 100 admissions, followed by the medical units at 6.1 (95% CI 4.7 to 7.7) per 1000 patients-days and 4.8 (95% CI 3.8 to 6.1) per 100 admissions ([table 4](#BMJOPEN2015010831TB4){ref-type="table"}).

###### 

Classification of incidence of adverse drug events (ADEs) by type of service

  Unit       ADEs   Patient-days, n   ADE crude rate per 1000 patient-days (95% CI)   Admissions, n   ADE incidence per 100 admissions (95% CI)
  ---------- ------ ----------------- ----------------------------------------------- --------------- -------------------------------------------
  Medical    66     10 767            6.1 (4.7 to 7.7)                                1352            4.8 (3.8 to 6.1)
  Surgical   29     9310              3.1 (2.1 to 4.4)                                1771            1.6 (1.1 to 2.3)
  ICU        150    10 919            13.7 (11.6 to 16.1)                             862             17.4 (14.7 to 20.3)

ICU, intensive care unit.

Medication classes involved in ADEs, PADEs and medication errors with low risk of causing harm {#s3e}
----------------------------------------------------------------------------------------------

Anticoagulants (21.6%) and antibiotics (20.8%) were the most common medication classes associated with ADEs. Medication classes most commonly associated with PADEs were antibiotics (31.3%) followed by anticoagulants (17.3%) and antihypertensives (9.3%) ([table 5](#BMJOPEN2015010831TB5){ref-type="table"}).

###### 

Medication classes involved in adverse drug events (ADEs), potential ADEs (PADEs) and medication errors with low risk of causing harm

  Medication class           ADEs, n (%) (N=245)   PADEs, n (%) (N=677)   Medication errors with low risk of causing harm, n (%) (N=609)
  -------------------------- --------------------- ---------------------- ----------------------------------------------------------------
  Antibiotics                51 (20.8)             212 (31.3)             193 (31.7)
  Anticoagulants             53 (21.6)             117 (17.3)             92 (15.1)
  Antihypertensives          49 (20)               63 (9.3)               61 (10)
  NSAIDs                     11 (4.5)              41 (6.1)               55 (9)
  GI medicines               4 (1.6)               43 (6.4)               39 (6.4)
  Antidiabetics              5 (2)                 32 (4.7)               26 (4.3)
  Steroids                   14 (5.7)              12 (1.8)               17 (2.8)
  Electrolytes               7 (2.9)               19 (2.8)               6 (1)
  Cardiovascular medicines   4 (1.6)               15 (2.2)               11 (1.8)
  Dyslipidaemic agents       7 (2.9)               16 (2.4)               6 (1)
  Analgesics                 4 (1.6)               9 (1.3)                15 (2.5)
  Antiasthmatics             5 (2)                 14 (2.1)               6 (1)
  Antituberculosis           3 (1.2)               11 (1.6)               7 (1.1)
  Vitamins                   0                     8 (1.2)                5 (0.8)
  Antifungals                1 (0.5)               4 (0.6)                6 (1)
  Antiseizures               5 (2)                 3 (0.4)                2 (0.3)
  Antipsychotics             1 (0.5)               3 (0.4)                6 (1)
  Thyroid agents             0                     5 (0.7)                3 (0.5)
  Antivirals                 4 (1.6)               2 (0.3)                1 (0.2)
  Antihistamines             1 (0.5)               3 (0.4)                1 (0.2)
  Sedatives                  4 (1.6)               1 (0.1)                0
  Anticancers                0                     3 (0.4)                2 (0.3)
  Others                     12 (4.9)              41 (6.1)               49 (8)

GI, gastrointestinal; NSAID, non-steroidal anti-inflammatory drug.

Agreement of physicians' reviews on the classification of the incidents {#s3f}
-----------------------------------------------------------------------

The κ value was 0.71 for the presence of ADEs, 0.67 for the presence of medication errors, and 0.62 for the presence of PADEs. The κ value for preventability of ADEs was 0.68 (definitely or probably preventable vs definitely or probably not preventable). For the severity of ADEs, the κ value was 0.74 (fatal vs significant, serious or life-threatening), 0.63 (life-threatening vs significant, serious or fatal), 0.52 (significant vs serious, life-threatening or fatal), and 0.48 (serious vs life-threatening or fatal) ([table 6](#BMJOPEN2015010831TB6){ref-type="table"}).

###### 

Inter-rater reliability of the incident type and their severity and preventability

  Severity                                            Agreement, %   κ value
  --------------------------------------------------- -------------- ---------
  Exclude vs ADEs, PADE or medication error           56.4           0.63
  ADEs vs PADE, medication error or exclude           93.6           0.71
  PADEs vs ADE, medication error or exclude           70.9           0.62
  Medication error vs ADEs, PADE or exclude           93.7           0.67
  Preventable vs non-preventable ADEs                 92.2           0.68
  Fatal vs life-threatening, serious or significant   100            0.74
  Life-threatening vs fatal, serious or significant   100            0.63
  Serious vs fatal, life-threatening or significant   60.5           0.48
  Significant vs fatal, life-threatening or serious   84.2           0.52

ADE, adverse drug event; PADE, potential ADE.

Factors associated with ADEs {#s3g}
----------------------------

Factors significantly associated with ADEs included age (OR 1.012; 95% CI 1.003 to 1.021), number of medications (OR 1.062; 95% CI 1.008 to 1.119), length of hospital stay (OR 1.025; 95% CI 1.015 to 1.035) and admission to ICUs (OR 3.276; 95% CI 2.005 to 5.354) and medical units (OR 1.736; 95% CI 1.078 to 2.796) ([table 7](#BMJOPEN2015010831TB7){ref-type="table"}). Gender was not significantly associated with ADEs (p=0.248); therefore, it was not included in the multivariate analysis.

###### 

Factors associated with adverse drug events

                                                 95% CI   p Value   Adjusted OR   95% CI   p Value           
  -------------------------------------- ------- -------- --------- ------------- -------- --------- ------- ---------
  Age                                    1.024   1.017    1.032     \<0.001       1.012    1.003     1.021   0.009
  Number of medications                  1.193   1.148    1.240     \<0.001       1.062    1.008     1.119   0.023
  Charlson\'s Comorbidity Index weight   1.251   1.158    1.352     \<0.001       1.041    0.937     1.157   0.452
  Length of hospital stay                1.042   1.034    1.051     \<0.001       1.025    1.015     1.035   \<0.001
  Gender (male)\*                        0.848   0.642    1.121     0.248         --       --        --      --
  ICU†                                   7.786   5.259    11.528    \<0.001       3.276    2.005     5.354   \<0.001
  Medical unit†                          2.539   1.664    3.872     \<0.001       1.736    1.078     2.796   0.023

\*Reference category: female.

†Reference category: surgery.

ICU, intensive care unit.

Discussion {#s4}
==========

In this study we evaluated the incidence of ADEs and found that they were common, with one-third caused by medication errors judged to be preventable. Errors resulting from preventable ADEs were most common at the prescribing stage followed by the dispensing and administering stages. Most of the preventable ADEs were judged to be serious. The incidence of ADEs reported in our study is similar to that found in previous studies.[@R2] [@R5] However, a higher incidence was reported in Japan.[@R4] The differences between our study results and the results from the Japanese study could be due to the longer hospital stay in Japan and differences in healthcare systems between the countries. The similarity between our findings and the US study may be due to the use of the same methods for data collection, ADE detection, and event classification and the similarities in the healthcare systems. The incidence at the prescribing stage in our study was higher than reported in Malaysia (25.15%),[@R12] Indonesia (20.4%)[@R13] and Thailand (1%).[@R14]

The κ values reported in our study range from substantial to moderate according to the measure of the strength of agreement suggested by Landis and Koch.[@R15] The lowest level of agreement in the present study was reported for judgement regarding the severity of the incidents (0.48 and 0.52). However, a similar study reported κ values lower than those found in our study (0.32 and 0.37).[@R2]

We included 3985 patients and found 245 ADEs, of which 35% were judged to be preventable. Gurwitz *et al*[@R8] identified 546 ADEs during 2403 nursing home residence admissions and reported that 51% of the observed ADEs were preventable. Bates *et al*[@R2] determined the incidence of ADEs in 4031 patients and found 247 ADEs, of which 28% were deemed preventable. In 2009, Hug *et al*[@R16] assessed the occurrence of ADEs in 1200 patients from six community hospitals and identified 180 ADEs, of which 75% were preventable. A multicentre cohort study of 3459 patients identified 1010 ADEs and found that 14% of the identified ADEs were preventable.[@R4]

Regarding PADEs, we noticed that only one-third of the events were intercepted. It is noteworthy to highlight that three of the four hospitals had clinical pharmacists monitoring patient treatments and most of the intercepted PADEs were in those hospitals.

Our study revealed that ADEs were associated with admission to ICUs and older age. Consistent with our results, other studies also reported that admission to ICUs[@R4] [@R17] and older age[@R4] [@R8] were major factors associated with ADEs. In support of this finding, perhaps special care should be given to older people who are admitted to ICUs because of the added risk of combining two risk factors.

Several important basic medication safety practices are not widely adopted in most Saudi hospitals.[@R18] [@R19] Therefore, there are opportunities for improving the safe use of medications and preventing ADEs in hospitals in Saudi Arabia. On a national level, the Saudi Food Drug Authority may lead efforts to prevent ADRs, and the Saudi Medication Safety Centre may lead initiatives to prevent medication errors. For example, the use of pharmacists to ascertain complete medication histories at admission and provide discharge counselling reduced the incidence of ADEs.[@R20] [@R21] Although reporting is a good tool to identify and prevent ADEs, under-reporting is a common challenge in Saudi hospitals.[@R22]

There is lack of literature about incident medication errors in South-East Asian[@R23] and Middle Eastern countries.[@R24] Future research could focus on investigating the causes of ADEs that occur during the medication use process, especially at the prescribing stage. More research is needed on the causes of ADEs using both qualitative and quantitative methodologies with the use of standard definitions of events and severity classification. Using methods similar to those used in this study, the benefits of interventions to prevent ADEs can be estimated and compared with a rigorously determined baseline.

This study is limited by a lack of hospitals from small towns and rural areas and it is thought that these settings have an even higher incidence of ADEs. Finally, our study findings are not generalisable to Saudi Arabia overall because the study was conducted in Riyadh only.

In conclusion, ADEs are common in Saudi hospitals, especially in the ICUs, causing significant morbidity and mortality. While there are variations in the incidence of ADEs among countries, there are prospects for preventing them. Interventions that are effective in other countries should be tested in Saudi Arabia. Such interventions may include, but are not limited to, implementation of computerised physician entry with a clinical decision support system,[@R16] involvement of clinical pharmacists as part of the medical team during physicians' rounds,[@R25] medication reconciliation to obtain accurate medication histories at hospital admission, unit transfers during hospitalisation and discharge from hospital,[@R28] and changing the currently available paper-based system to an electronic medical records system.[@R29]
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